{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-048525","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.898233+00:00","generated_at":"2026-05-17T00:33:04.723886+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Madrigal Q3 2025 Rezdiffra sales $287.3M, annualizing >$1B; licenses oral GLP-1","bullets":["Rezdiffra net sales $287.3M in Q3 2025 vs $62.2M YoY; >29,500 patients on therapy.","Operating expenses $401.2M (R&D $174M incl upfront for CSPC, SG&A $209.1M).","Cash $1.1B; licensed global rights to oral GLP-1 (MGL-2086) from CSPC; clinic entry H1 2026.","New Orange Book patent for Rezdiffra covering weight-threshold dosing into 2045.","Launched Rezdiffra in Germany after EC conditional approval in August 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-048525","json":"https://secwatch.observer/filing/0001628280-25-048525.json","markdown":"https://secwatch.observer/filing/0001628280-25-048525.md","text":"https://secwatch.observer/filing/0001628280-25-048525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025048525/0001628280-25-048525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025048525/mdgl-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:33:04.723886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}